TPIDB > Principal Investigator
Principal Investigator
National Taiwan University Hospital
(在職)
Division of Hematology & Oncology
Division of General Surgery
Division of Nuclear Medicine
Digestive System Department
Division of General Internal Medicine
更新時間：2023-09-19
許駿Hsu, Chiun
- Principal Investigator
- Clinical Trial Experience (year) 23 years 9 個月
Publication
29Publications
1
Chang FC, Chen TW, Huang TT, Lin WC, Liu JS, Chiang WC, Chen YM, Hsu C, Yeh KH, Chu TS. Spectrum of cancer patients receiving renal biopsy. J Formos Med Assoc. 2022 Jan;121(1 Pt 1):152-161. doi: 10.1016/j.jfma.2021.02.009. Epub 2021 Feb 25. PMID: 33640191.
2
Hsieh CH, Jian CZ, Lin LI, Low GS, Ou PY, Hsu C, Ou DL. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer. Cancers (Basel). 2022 Jan 7;14(2):294. doi: 10.3390/cancers14020294. PMID: 35053457; PMCID: PMC8774093.
3
Shao YY, Wang SY, Lin SM; Diagnosis Group,; Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021 Apr;120(4):1051-1060. doi: 10.1016/j.jfma.2020.10.031. Epub 2020 Nov 14. PMID: 33199101.
4
Chen BB, Lin ZZ, Shao YY, Hsu C, Hsu CH, Cheng AL, Liang PC, Shih TT. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials. Cancers (Basel). 2021 Oct 1;13(19):4962. doi: 10.3390/cancers13194962. PMID: 34638446; PMCID: PMC8508238.
5
Shao YY, Sun NY, Jeng YM, Wu YM, Hsu C, Hsu CH, Hsu HC, Cheng AL, Lin ZZ. Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma. Cells. 2021 Jul 5;10(7):1698. doi: 10.3390/cells10071698. PMID: 34359867; PMCID: PMC8303881.
6
Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc. 2021 Aug;120(8):1581-1590. doi: 10.1016/j.jfma.2020.11.015. Epub 2020 Dec 15. PMID: 33334658.
7
Hung YP, Shao YY, Lee JM, Hsu C, Hsu CH, Yang MH, Chao Y. Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. J Chin Med Assoc. 2021 Feb 1;84(2):144-150. doi: 10.1097/JCMA.0000000000000477. PMID: 33433132.
8
Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020 Jul 1;126(13):3021-3030. doi: 10.1002/cncr.32883. Epub 2020 Apr 22. PMID: 32320048.
9
Chen MH, Chou WC, Hsiao CF, Jiang SS, Tsai HJ, Liu YC, Hsu C, Shan YS, Hung YP, Hsich CH, Chiu CH, Liu TC, Cho SF, Liu TW, Chao Y. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist. 2020 May;25(5):e782-e788. doi: 10.1634/theoncologist.2019-0490. Epub 2019 Dec 18. PMID: 31852810; PMCID: PMC7216444.
10
Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Eur J Cancer. 2020 Jan;124:123-130. doi: 10.1016/j.ejca.2019.10.023. Epub 2019 Nov 22. PMID: 31765987.
